PET Scanner Developed for Cardiac Perfusion Imaging

Positron Corp. (Fishers, IN, USA), a cardiac molecular imaging solutions company, announced that the US Food and Drug Administration (FDA) has approved Neusoft Positron Medical Systems 510(k) submission for its Attrius PET scanner product line developed by the company and its joint venture with Neusoft Medical Systems (Shenyang, China). Positron's Attrius product line was developed to provide physicians a state-of-the-art cardiac PET molecular imaging system.

Joseph Oliverio, president of Positron, stated, "We believe that a significant market demand exists for a technology improvement in nuclear cardiology at an affordable cost of entry. Our Attrius device was specifically developed for cardiac molecular imaging and can provide patients with an accurate diagnosis resulting in cost-savings to our healthcare system, the ability to track the efficacy of therapy, the potential for improved patient outcomes, and help emergency room physicians see the result of a patient's chest pain without the need for an angiogram. This FDA approval allows us to immediately ramp up our sales and marketing efforts, as we will offer the Attrius to the more than 4,000 cardiology offices and 3,000 target hospitals. The company feels its Attrius PET scanner is the solution that thousands of cardiology groups are looking for to improve their bottom line, reduce healthcare costs, and provide patients with a superior diagnosis of coronary artery disease.”

Related Links:
Positron
Neusoft Medical Systems